Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry describes a therapeutic intervention or mechanism of action, not a discrete molecular target. It is a non-pharmacological strategy for gastroesophageal reflux prevention, involving the physical thickening of gastric contents (e.g., using cereal, starch, or other thickeners). The mechanism of action is based on increasing the viscosity of stomach contents, which may reduce regurgitation by slowing bolus transit and limiting refluxate height in the esophagus. It is considered a first-line therapy for GERD in infants and young children. However, it does not represent a molecular entity like a receptor, enzyme, transporter, or protein that drugs would typically interact with, and therefore does not fit the definition of a 'therapeutic target' in drug development.
Increasing the viscosity of gastric contents, which may reduce regurgitation by slowing bolus transit and limiting refluxate height in the esophagus. This is a physical/rheological modification rather than a drug-target interaction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastroesophageal Reflux Prevention via Physical Thickening of Gastric Contents.